Enoxaparin - A low molecular weight heparin, restores the altered vascular reactivity of resistance arteries in aged and aged-diabetic hamsters

Vascular Pharmacology

Volumn 40, Issue 3, 2003, Pages 167-174

  Georgescu, Adriana ^a   Popov, Doina ^a   Capraru, Monica ^b   Simionescu, Maya ^a  

^a INSTITUTE OF CELLULAR BIOLOGY AND PATHOLOGY NICOLAE SIMIONESCU   (Romania)

^b Department of Rheumatology   (Romania)

Author keywords

Diabetes; Enoxaparin; Heparin

Indexed keywords

ACETYLCHOLINE; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NORADRENALIN; POTASSIUM;

AGING; ANIMAL MODEL; ARTERY RESISTANCE; ARTERY WALL; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFECT; ENDOTHELIUM; FRACTIONATION; HAMSTER; MEDICAL ASSESSMENT; MICROVASCULATURE; MYOGRAPHY; NONHUMAN; PRIORITY JOURNAL;

ACETYLCHOLINE; AGE FACTORS; ANIMALS; ANTICOAGULANTS; BLOOD GLUCOSE; CHOLESTEROL; CRICETINAE; DIABETES MELLITUS, EXPERIMENTAL; ENDOTHELIUM, VASCULAR; ENOXAPARIN; HEPARIN; MALE; MESENTERIC ARTERIES; MUSCLE CONTRACTION; MYOGRAPHY; NOREPINEPHRINE; POTASSIUM; VASCULAR RESISTANCE; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 0042334862     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1537-1891(03)00041-7     Document Type: Article

References (46)

1. Bachetti T., Pasini E., Clini E., Cremona G., Ferrari R. High-dose heparin impairs nitric oxide pathway and vasomotion in rats. Circulation. 99:1999;2861-2863.
2. Baldus S., Eiserich J.P., Mani A., Castro L., Figueroa M., Chumley P., Ma W.X., Tousson A., White C.R., Bullard D.C., Brennan M.L., Lusis A.J., Moore K.P., Freeman B.A. Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. J. Clin. Invest. 108(12):2001;1759-1770.
3. Benchetrit S., Mandelbaum A., Bernheim J., Podjarny E., Green J., Katz B., Rathaus M. Altered vascular reactivity following partial nephrectomy in the rat: a possible mechanism of the blood-pressure-lowering effect of heparin. Nephrol. Dial. Transplant. 14:1999;64-69.
4. Bretschneider E., Schror K. Cellular effects of factor Xa on vascular smooth muscle cells - inhibition by heparins? Semin. Thromb. Hemost. 27:2001;489-493.
5. Chulia T., Gonzales P., Del Rio M., Tejerina T. Comparative study of elgodipine and nisoldipine on the contractile response of various isolated blood vessels. Eur. J. Pharmacol. 285:1995;115-122.
6. Cohen M. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes. J. Invasive Cardiol. 12:2000;E5-E9.
7. Dobosz M., Hac S., Mionskowska L., Dobrowolski S., Wajda Z. Microcirculatory disturbances of the pancreas in cerulein-induced acute pancreatitis in rats with reference to L-arginine, heparin, and procaine treatment. Pharmacol. Res. 36(2):1997;123-128.
8. Ferguson J.J. Combining low-molecular-weight heparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: the NICE 3 story. J. Invasive Cardiol. 12:2000;E10-E13.
9. Guretzki H.J., Schleicher E., Gerbitz K.D., Olgemoeller B. Heparin induces endothelial extracellular matrix alterations and barrier dysfunction. Am. J. Physiol. 267:1994;C946-C954.
10. Hirsh J. Low-molecular-weight heparin for the treatment of venous thromboembolism. Am. Heart J. 135:1998;S336-S342.
11. Hirsh J. Recent clinical trials in the treatment of venous thromboembolism and unstable angina with low molecular weight heparins. Curr. Opin. Hematol. 5:1998;360-365.
12. Hirsh J. Low-molecular-weight heparin. A review of the results of recent studies of the treatment of venous thromboembolism and unstable angina. Circulation. 98:1998;1575-1582.
13. Hirsh J., Warkentin Th.E., Raschke R., Granger C., Ohman E.M., Dalen J.E. Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 114:1998;489S-510S.
14. Kouretas P.C., Kim Y.D., Cahill P.A., Myers A.K., To L.N., Wang Y.N. Heparin preserves nitric oxide activity in coronary endothelium during ischemia-reperfusion injury. Ann. Thorac. Surg. 66:1998;1210-1215.
15. Manduteanu I., Voinea M., Capraru M., Dragomir E., Simionescu M. A novel attribute of enoxaparin: inhibition of monocyte adhesion to endothelial cells by a mechanism involving cell adhesion molecules. Pharmacology. 65:2002;32-37.
16. Mishra-Gorur K., Castellot J.J. Heparin rapidly and selectively regulates protein tyrosine phosphorylation in vascular smooth muscle cells. J. Cell. Physiol. 178:1999;205-215.
17. Montalescot G., Philippe F., Ankri A., Vicaut E., Bearez E., Poulard J.E., Carrie D., Flammang D., Dutoit A., Carayon A., Jardel C., Chevrot M., Bastard J.P., Bigonzi F., Thomas D. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease. Beneficial effects of enoxaparin. Circulation. 98:1998;294-299.
18. Muir J.M., Andrew M., Hirsh J., Weitz J.I., Young E., Deschamps P., Shaughnessy S.G. Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. Blood. 88:1996;1314-1320.
19. Mulvany M.J., Halpern W. Contractile properties of small arteriolar resistance vessels in spontaneously hypertensive and normotensive rats. Circ. Res. 41:1997;19-26.
20. Nistor A., Bulla A.A., Filip D.A., Radu A. The hyperlipidemic hamster as a model of experimental atherosclerosis. Atherosclerosis. 68:1987;159-173.
21. O'Brien B.J., Willan A., Blackhouse G., Goeree R., Cohen M., Goodman S. Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada? Am. Heart J. 139:2000;423-429.
22. Ohtani H. Effects of dietary cholesterol and fatty acids on plasma cholesterol and hepatic lipoprotein metabolism. J. Lipid Res. 31:1990;1413-1422.
23. Pacheco H., Kerdel F. Successful treatment of lichen planus with low-molecular-weight heparin: a case series of seven patients. J. Derm. Treat. 12:2001;123-126.
24. Popov D., Simionescu M. Alterations of lung structure in experimental diabetes, and diabetes associated with hyperlipidemia in hamsters. Eur. Respir. J. 10:1997;1850-1858.
25. Pukac L.A., Carter J.E., Ottlinger M.E., Karnovsky M.J. Mechanisms of inhibition by heparin of PDGF stimulated MAP kinase activation in vascular smooth muscle cells. J. Cell. Physiol. 172:1997;69-78.
26. Purcell H., Fox K.M. Current roles and further possibilities for low molecular weight heparins in unstable angina. Eur. Heart J. 19(Suppl. K):1998;K18-K23.
27. Reach I., Thebaud H.E., Dupuy C.A., Kuntziger H., Debure A., Fievet P., Thoumazou G., de Groc F., Teboulle D., Combe S. Optimization of enoxaparin dose in the prevention of coagulation in the circuits hemodialysis: results of a multicenter study. Nephrologie. 15:1994;395-401.
28. Sanderink G.J., Guimart C.G., Ozoux M.L., Jarivalla N.U., Shukla U.A., Boutouyrie B.X. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb. Res. 105:2002;225-231.
29. Sanson B.J., Lensing A.W.A., Prins M.H., Ginsberg J.S., Barkagan Z.S., Lavenne-Pardonge E., Brenner B., Dulitzky M., Nielsen J.D., Boda Z., Turi S., Mac Gillavry M.R., Hamulyak K., Theunissen I.M., Hunt B.J., Buller H.R. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb. Haemost. 81:1999;668-672.
30. Schlaifer J.D., Mills R.M. Effects of low molecular weight heparin on coronary endothelial function in acute cellular heart transplant rejection. Am. J. Cardiol. 86:2000;117-120.
31. Simionescu M., Popov D., Sima A., Hasu M., Costache G., Faitar S., Vulpanovici A., Stancu C., Stern D., Simionescu N. Pathobiochemistry of combined diabetes and atherosclerosis studied on a novel animal model: the hyperlipemic hyperglycemic hamster. Am. J. Pathol. 148:1996;997-1014.
32. Solini A., Vergnani L., Ricci F., Crepaldi G. Glycosaminiglycans delay the progression of nephropathy in NIDDM. Diabetes Care. 20:1997;813-817.
33. Stutzmann J.M., Mary V., Wahl F., Grosjean-Piot O., Uzan A., Pratt J. Neuroprotective profile of enoxaparin, a low molecular weight heparin, in vivo models of cerebral ischemia or traumatic brain injury in rats: a review. CNS Drug Rev. 8:2002;1-30.
34. Sullivan M.P., Cerda J.J., Robbins F.L., Burgin C.W., Beatty R.J. The gerbil, hamster and guinea pig as rodent models for hyperlipidemia. Lab. Anim. Sci. 43:1993;575-578.
35. Tangphao O., Chalon S., Moreno H.J., Abiose A.K., Blaschke T.F., Hoffman B.B. Heparin-induced vasodilation in human hand veins. Clin. Pharmacol. Ther. 66:1999;232-238.
36. Thurston G., Baldwin A.L., Wilson L.M. Changes in endothelial actin cytoskeleton at leakage sites in the rat mesenteric vasculature. Am. J. Physiol. 266:1995;H316-H329.
37. Tiefenbacher C.P., Chilian W.M. Basic fibroblast growth factor and heparin influence coronary arteriolar tone by causing endothelium-dependent dilation. Cardiovasc. Res. 34:1997;411-417.
38. Tomioka T., Fujii H., Hirota M., Ueno K., Pour P.M. The patterns of beta-cell regeneration in untreated diabetic and insulin-treated diabetic Syrian hamsters after streptozotocin treatment. Int. J. Pancreatol. 8:1991;355-366.
39. Turpie A.G.G. Can we differentiate the low-molecular-weight heparins? Clin. Cardiol. 23:2000;I-4-I-7.
40. Vasdev S., Ford C.A., Longerich L., Barret B., Parai S., Campbell N. Oral treatment with low molecular weight heparin normalizes blood pressure in hypertensive rats. Artery. 21:1994;1-28.
41. Waters D.D., Azar R.R. Low molecular-weight heparins for unstable angina: a better mousetrap? Circulation. 96:1997;3-5.
42. Wessel H.P., Iberg N. The smooth muscle cell antiproliferative activity of heparin sulfate model oligosaccharides. Bioorg. Med. Chem. Lett. 6(4):1996;427-430.
43. Wilson S.K., Solez K., Boitnott J., Heptinstall R.H. The effect of heparin treatment of hypertension and vascular lesions in stroke prone spontaneously hypertensive rats. Am. J. Pathol. 102:1981;62-71.
44. Young E., Wells P., Holloway S., Weitz J., Hirsh J. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than UFH. Thromb. Haemost. 71:1994;300-304.
45. Zed P.J., Tisdale J.E., Borzak S. Low-molecular-weight heparins in the management of acute coronary syndromes. Arch. Intern. Med. 159:1999;1849-1857.
46. Zhao Y.-J., Wang J., Rubin L.J., Yuan X.J. Inhibition of Kv and Kca channels antagonizes NO-induced relaxation in pulmonary artery. Am. J. Physiol. 272:1997;H904-H912.